Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) 是一种有效的选择性蛋白激酶 C (PKC) 抑制剂，对大鼠脑 PKC 的IC50为 158 nM。Bisindolylmaleimide VIII acetate 对 PKC-α，PKC-βI，PKC-βII，PKC-γ，PKC-ε 的 IC50分别为 53、195、163、213 和 175 nM。Bisindolylmaleimide VIII acetate 促进 Fas 介导的细胞凋亡 (apoptosis)，并抑制 T 细胞介导的自身免疫性疾病。
| 生物活性 | Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selectiveprotein kinase C (PKC)inhibitor with anIC50of 158 nM for rat brainPKC. Bisindolylmaleimide VIII acetate has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively[1]. Bisindolylmaleimide VIII acetate facilitates Fas-mediatedapoptosisand inhibits T cell-mediated autoimmune diseases[2]. |
| IC50& Target | Rat Brain PKC 158 nM (IC50) | PKC-α 53 nM (IC50) | PKC-βI 195 nM (IC50) | PKC-βII 163 nM (IC50) | PKC-γ 213 nM (IC50) | PKC-ε 175 nM (IC50) |
|
体外研究
(In Vitro) | Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate; 5 μM; 8, 12 hours) dramatically increases TRA-8-induced cell death in time-dependent and TRA-8 dose-dependent manners[2].
Bisindolylmaleimide VIII acetate (5 μM; 6 hours) significantly decreases procaspase-8 at 4 h and completely disappeares at 6 h after the combined treatment with TRA-8[2].
Apoptosis Analysis[2] | Cell Line: | 1321N1 cells | | Concentration: | 5 μM | | Incubation Time: | 8, 12 hours | | Result: | Dramatically increased TRA-8-induced cell death in time-dependent and TRA-8 dose-dependent manners. |
Western Blot Analysis[2] | Cell Line: | 1321N1 cells | | Concentration: | 5 μM | | Incubation Time: | 6 hours | | Result: | Significantly decreased procaspase-8 at 4 h and completely disappeared at 6 h. |
|
体内研究
(In Vivo) | Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate; 100 μg; IP; every other day for three doses) results in nearly complete tumor regression combined toTRA-8. The treatment with Bisindolylmaleimide VIII acetate alone does not induce significant tumor regression[2].
| Animal Model: | 6-8-week-old female NOD/SCID mice[2].
| | Dosage: | 100 μg | | Administration: | IP; every other day for three doses | | Result: | Resulted in nearly complete tumor regression combined toTRA-8. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: DMSO : 250 mg/mL(545.24 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.1810 mL | 10.9049 mL | 21.8098 mL | | 5 mM | 0.4362 mL | 2.1810 mL | 4.3620 mL | | 10 mM | 0.2181 mL | 1.0905 mL | 2.1810 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.54 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.54 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
